









Markets
/
Stocks
/
nasdaq-npce
/

Neuropace Inc

NPCE

13.120USD

+0.340+2.66%

Close 11/07, 16:00（ET）Quotes delayed by 15 min

436.65MMarket Cap

LossP/E TTM



Neuropace Inc

13.120

+0.340+2.66%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Neuropace Inc

Currency: USD Updated: 2025-11-07

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Neuropace Inc's Score

Industry at a Glance

Industry Ranking

23 / 209

Overall Ranking

76 / 4614

Industry

Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 8 analysts

Buy

Current Rating

17.500

Target Price

+33.38%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Neuropace Inc Highlights

StrengthsRisks

NeuroPace, Inc. is a medical device company. The Company is focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is a brain-responsive platform that delivers personalized, real-time treatment at the seizure source. The Company has developed its RNS System to address the individualized nature of drug-resistant epilepsy and deliver a safe therapy for focal onset seizures anywhere in the brain. The RNS System is a device that records brain activity data and allows clinicians to monitor patients not only in person, but also remotely. RNS System monitors and analyzes the brain’s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Company’s RNS System is also engaged in treating other brain disorders, including depression, impulse control disorders, memory disorders, and post-traumatic stress disorder.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 75.54% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 79.91M.

Undervalued

The company’s latest PE is -17.50, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 30.31M shares, decreasing 11.36% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 1.25K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.28.

Financial Health

Currency: USD Updated: 2025-11-07

The company's current financial score is 7.64, which is higher than the Healthcare Equipment & Supplies industry's average of 7.46. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 27.35M, representing a year-over-year increase of 29.89%, while its net profit experienced a year-over-year increase of 35.88%.

Score

Industry at a Glance

Previous score

7.64

Change



Financials

5.81

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

6.90

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

8.13

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.36

Key Metrics

Free cash flow

No Data

Neuropace Inc's Company Valuation

Currency: USD Updated: 2025-11-07

The company’s current valuation score is 7.15, which is lower than the Healthcare Equipment & Supplies industry's average of 7.19. Its current P/E ratio is -17.50, which is -95.70% below the recent high of -0.75 and -25.52% above the recent low of -21.96.

Score

Industry at a Glance

Previous score

7.15

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 23/209

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-07

The company’s current earnings forecast score is 8.50, which is higher than the Healthcare Equipment & Supplies industry's average of 7.74. The average price target for Neuropace Inc is 18.00, with a high of 20.00 and a low of 15.00.

Score

Industry at a Glance

Previous score

8.50

Change

Support & Resistance

No Data

Analyst Rating

Based on 8 analysts

Buy

Current Rating

17.500

Target Price

+33.38%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

Neuropace Inc

NPCE

Boston Scientific Corp

BSX

Edwards Lifesciences Corp

Intuitive Surgical Inc

ISRG

Veeva Systems Inc

VEEV

Thermo Fisher Scientific Inc

TMO

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-07

The company’s current price momentum score is 9.45, which is higher than the Healthcare Equipment & Supplies industry's average of 6.88. Sideways: Currently, the stock price is trading between the resistance level at 14.88 and the support level at 10.29, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.34

Change

0.11

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MACD(12,26,9)

0.541

Buy

RSI(14)

70.731

Buy

STOCH(KDJ)(9,3,3)

73.500

Buy

ATR(14)

0.780

High Vlolatility

CCI(14)

170.397

Buy

Williams %R

15.031

Overbought

TRIX(12,20)

0.208

Sell

StochRSI(14)

98.402

Overbought

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

11.536

Buy

MA10

10.883

Buy

MA20

10.778

Buy

MA50

10.368

Buy

MA100

9.898

Buy

MA200

11.290

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-07

The company’s current institutional recognition score is 10.00, which is higher than the Healthcare Equipment & Supplies industry's average of 6.42. The latest institutional shareholding proportion is 91.62%, representing a quarter-over-quarter increase of 3.17%. The largest institutional shareholder is The Vanguard, holding a total of 1.37M shares, representing 4.14% of shares outstanding, with 18.01% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Accelmed Growth Partners Management Ltd

4.43M

Soleus Capital Management, L.P.

2.31M

-11.32%

OrbiMed Advisors, LLC

2.61M

-23.26%

Morgan Stanley & Co. LLC

2.58M

+2.08%

BlackRock Institutional Trust Company, N.A.

1.54M

+109.91%

The Vanguard Group, Inc.

Star Investors

1.37M

+14.29%

First Light Asset Management, LLC

1.38M

-12.86%

Armistice Capital LLC

1.15M

-0.11%

Driehaus Capital Management, LLC

1.01M

+25.13%

Risk Assessment

Currency: USD Updated: 2025-11-07

The company’s current risk assessment score is 4.92, which is higher than the Healthcare Equipment & Supplies industry's average of 4.58. The company's beta value is 1.86. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.